Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

  • ID: 4430360
  • Report
  • Region: Global
  • 88 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals
  • Bausch & Lomb
  • Celgene
  • GE Healthcare
  • Ipsen
  • Merck
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Nanoparticles

Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi-synthetic polymers. These are used in biotechnology and pharmaceutical sectors for studying biological systems for diagnosing diseases and focusing on treatment at the molecular level. The properties of many conventional materials alter when formed from nanoparticles, the reason being nanoparticles have a greater surface area per weight than larger particles, making them more reactive to other molecules

The analysts forecast the global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis
Other prominent vendors
  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB
Market drivers
  • Rising R&D expenditure in pharmaceutical and biotechnology sectors
  • For a full, detailed list, view the full report
Market challenges
  • Challenges in development of nanoparticles for therapeutics
  • For a full, detailed list, view the full report
Market trends
  • Increasing demand for nanoparticles in stem cell therapy
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals
  • Bausch & Lomb
  • Celgene
  • GE Healthcare
  • Ipsen
  • Merck
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Market size and forecast
  • Five forces analysis
PART 06: MARKET SEGMENTATION BY END-USER
  • Comparison by end-user
  • Biotechnology
  • Pharmaceutical
  • Market opportunity by end-user
PART 07: REGIONAL LANDSCAPE
  • Regional comparison
  • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
  • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
  • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
  • Market opportunity
PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS
  • Increasing demand for nanoparticles in stem cell therapy
  • Increasing prevalence of chronic diseases
  • Increasing use of gold nanoparticles
PART 11: VENDOR LANDSCAPE
  • Competitive scenario
  • Investment opportunity
PART 12: VENDOR ANALYSIS
  • Vendor overview
  • Merck
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Novartis
  • Other prominent vendors
PART 13: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Applications of nanoparticles in biotechnology and pharmaceutical sectors
Exhibit 02: Detection of cancer cells in bloodstream through use of nanoparticles
Exhibit 03: Global nanoparticles market in biotechnology and pharmaceutical sectors: Market overview
Exhibit 04: Global nanoparticles market in biotechnology and pharmaceutical sectors 2016-2021 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Global nanoparticles market in biotechnology and pharmaceutical sectors by end-user 2016-2021 (% share)
Exhibit 07: Comparison by end-user
Exhibit 08: Global nanoparticles market by biotechnology 2016-2021 ($ billions)
Exhibit 09: Global nanoparticles market by biotechnology - Year over year growth
Exhibit 10: Global nanoparticles market by pharmaceutical 2016-2021 ($ billions)
Exhibit 11: Nanoparticles in pharmaceuticals
Exhibit 12: Global nanoparticles market by pharmaceutical - Year over year growth
Exhibit 13: Global nanoparticles market in biotechnology and pharmaceutical sectors by region 2016-2021 (% share)
Exhibit 14: Regional comparison
Exhibit 15: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas 2016-2021 ($ billions)
Exhibit 16: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas - Year over year growth
Exhibit 17: Top 3 countries in Americas
Exhibit 18: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA 2016-2021 ($ billions)
Exhibit 19: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA - Year over year growth
Exhibit 20: Top 3 countries in EMEA
Exhibit 21: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC 2016-2021 ($ billions)
Exhibit 22: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC - Year over year growth
Exhibit 23: Top 3 countries in APAC
Exhibit 24: Nanoparticle-based products under clinical trials
Exhibit 25: Major chronic disease-related deaths 2012 (in thousands)
Exhibit 26: Strategic success factors for vendors to consider
Exhibit 27: Investment opportunity mapping
Exhibit 28: Merck: Profile
Exhibit 29: Merck: Strength analysis
Exhibit 30: Merck: Strategy assessment
Exhibit 31: Merck: Opportunity assessment
Exhibit 32: F. Hoffmann-La Roche: Profile
Exhibit 33: F. Hoffmann-La Roche: Strength analysis
Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 36: GE Healthcare: Profile
Exhibit 37: GE Healthcare: Strength analysis
Exhibit 38: GE Healthcare: Strategy assessment
Exhibit 39: GE Healthcare: Opportunity assessment
Exhibit 40: Novartis: Profile
Exhibit 41: Novartis: Strength analysis
Exhibit 42: Novartis: Strategy assessment
Exhibit 43: Novartis: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals
  • Bausch & Lomb
  • Celgene
  • GE Healthcare
  • Ipsen
  • Merck
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

The author of the report recognizes the following companies as the key players in the global nanoparticles market in biotechnology and pharmaceutical sectors: F. Hoffmann-La Roche, GE Healthcare, Merck, and Novartis

Other Prominent Vendors in the market are: AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth. Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells. Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.”

According to the report, one of the major drivers for this market is Rising R&D expenditure in pharmaceutical and biotechnology sectors. The pharmaceutical industry is witnessing a global surge in research funding to combat various rare diseases developing globally or to explore new therapies for existing conditions. The pharmaceutical R&D spending is expected to increase by 4% between 2016 to 2022. Biotechnology companies are also making increased investments in R&D. The US was the largest investor in biotechnology R&D in 2015 investing around $28 billion. France was the second largest investor in biotechnology R&D in 2015 investing over $3.6 billion, followed by Switzerland investing over $2.8 billion. South Korea was the largest investor in biotechnology R&D in Asia, investing over $1.7 billion.

Further, the report states that one of the major factors hindering the growth of this market is Challenges in development of nanoparticles for therapeutics. Although nanoparticle-based therapeutics overcome biological barriers by effectively delivering hydrophobic drugs at preferentially target sites of disease, only a small number of nanoparticle-based medicines have been approved for clinical use. Manufacturers of nanoparticles face numerous challenges and hurdles at different stages of product development. The complexity of nanoparticles requires careful design and engineering for their three-dimensional construction. Their development requires detailed analysis of orthogonal methods, pharmacological profiles, and biological behaviors. Nanoparticles require detailed characterization and the successful manufacture of these complex constructs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis
  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll